Angiotensin receptor-neprilysin inhibitor (ARNI)
- Sacubitril/valsartan = ARNI
- Preferred RAAS-pathway drug for many HFrEF pts
- ↓ HF hospitalization + CV death
- Also lowers BP
- Hyperkalemia, renal dysfunction, hypotension
- Angioedema risk; never combine with ACEi
- allow 36 h after ACE inhibitor
Class at a glance
- Sacubitril/valsartan = ARNI
Clinical role
- Preferred RAAS-pathway drug for many HFrEF pts
Practical pearls
- ↓ HF hospitalization + CV death
- Also lowers BP
Safety / monitoring
- Hyperkalemia, renal dysfunction, hypotension
- Angioedema risk; never combine with ACEi
- allow 36 h after ACE inhibitor
Self-check
- What key adverse effect/risk occurs with Angiotensin receptor-neprilysin inhibitor (ARNI)?
Angioedema risk; never combine with ACEi.
Drugs in this class (2)
All drug classes · Open the interactive console ↗
